BioCardia, Inc. (NASDAQ:BCDA) Short Interest Update

BioCardia, Inc. (NASDAQ:BCDA) was the recipient of a large decrease in short interest in November. As of November 30th, there was short interest totalling 103,600 shares, a decrease of 5.4% from the November 15th total of 109,500 shares. Currently, 2.9% of the shares of the company are short sold. Based on an average daily volume of 99,900 shares, the short-interest ratio is presently 1.0 days.

BioCardia Stock Up 0.5 %

BCDA stock opened at $2.09 on Tuesday. BioCardia has a 52 week low of $1.84 and a 52 week high of $10.79. The business has a 50-day simple moving average of $2.35 and a 200 day simple moving average of $2.79. The company has a market cap of $9.58 million, a PE ratio of -0.50 and a beta of 1.25.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and issued a $25.00 price target on shares of BioCardia in a research note on Thursday, November 14th.

BioCardia Company Profile

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.